Data disclosure in Jordan


Published on

Presentation by Abeer Rabayah, MeTA Jordan Secretariat / Technical Officer during the MeTA countries sharing meeting, London 2009.

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Data disclosure in Jordan

    1. 1. Pharmacist :Abeer Rabayah MeTA Jordan Secretariat/ Technical Officer Data Disclosure in Jordan MeTA 18/01/10
    2. 2. Type of data being collected <ul><li>Data in the four core areas that covers: </li></ul><ul><li>Polices/ laws and regulations </li></ul><ul><li>Practices and procedures </li></ul><ul><li>Availability status of each key disclosure data </li></ul><ul><li>Reasons behind unavailability of some data </li></ul><ul><li>Reasons behind not publishing /disclosing some of the available data </li></ul>18/01/10 MeTA
    3. 3. Overview of disclosure process and engagement of stakeholders  <ul><li>Data Disclosure Survey Tool was sent to all members by mail to have an overview. </li></ul><ul><li>Start discussing the tool and it’s rational with each committee especially within their areas of expertise and getting feedback on the best way to precede working. </li></ul><ul><li>Based on MeTA council members suggestion , the national MeTA Secretariat Organized three special MeTA Council Meetings to discuss the key disclosed data ( average spent time:2 hours per meeting). </li></ul><ul><li>Collected data was categorized in special tables in order to be verified and accurately referenced based on its official sources. </li></ul>18/01/10 MeTA
    4. 4. Challenges & lessons Learned <ul><li>Challenges </li></ul><ul><li>Most of key stakeholders who represent the official resources of Data have limited time. </li></ul><ul><li>Limited contribution from CSO members </li></ul><ul><li>Key disclosure Data regarding Medicines Availability to consumer is difficult to obtain ( WHO-HAI survey and Baseline pharmaceutical assessment survey is still ongoing) </li></ul><ul><li>Some key Data sources were not easily accessible (a fees is needed to obtain the data) </li></ul>18/01/10 MeTA
    5. 5. Challenges & lessons Learned <ul><li>Lessons Learned </li></ul><ul><li>Sharing Data among stakeholder is important to stimulate discussion and asking questions. </li></ul><ul><li>Data disclosure meeting raised some useful and important recommendations. </li></ul><ul><li>Stakeholders exchanged data among each other and learned new things that they didn't previously now. </li></ul><ul><li>Data disclosure meetings was an opportunity for different stakeholder to understand why some Data are not disclosed. </li></ul><ul><li>Data disclosure meetings uncovered some of the official website’s weaknesses that hinder accessibility to published data. </li></ul>18/01/10 MeTA
    6. 6. Type of support needed <ul><li>To conduct one workshop about the importance of Data Disclosure and its added value especially for the private sector as it consider most of its data confidential. </li></ul><ul><li>To support us in transforming Data disclosure to become a systemised process. </li></ul><ul><li>To exchange ideas and disclosure process with other countries where Data disclosure is more developed. </li></ul>18/01/10 MeTA
    7. 7. Data Disclosure Survey Tool 18/01/10 MeTA Lessons Learned Challenges
    8. 8. Thank you! <ul><li>Abeer Rabayah </li></ul><ul><li>[email_address] </li></ul><ul><li>+962 7 99555194 </li></ul><ul><li> </li></ul>18/01/10 MeTA